Impact of von Willebrand Disease on Costs and Patient Outcomes - Featuring a Patient Perspective

https://www.pharmacytimes.org/on-demand/impact-of-von-willebrand-disease-on-costs-and-patient-outcomes-featuring-a-patient-perspective-enduring

Related Videos

Related Content

Advertisement

May 23rd 2025

CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

Hayden E. Klein

A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.

May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville

Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.

May 23rd 2025

AJMC® in the Press, May 23, 2025

Julia Bonavitacola

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

May 22nd 2025

Can GLP-1 Receptor Agonists Curb Cancer? Study Links Drugs to Reduced Risk in Obesity-Related Cases

Mary Caffrey

Drugs first approved to treat diabetes, which later became a top sellers to aid weight loss, are associated with reduced risk of obesity-related cancer.

May 22nd 2025

AI Can Boost Accuracy When Classifying HER2-Low, HER2-Ultralow Breast Cancers, Findings Show

Mary Caffrey

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low breast cancers.

Related Content

Advertisement

May 23rd 2025

CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

Hayden E. Klein

A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.

May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville

Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.

May 23rd 2025

AJMC® in the Press, May 23, 2025

Julia Bonavitacola

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

May 22nd 2025

Can GLP-1 Receptor Agonists Curb Cancer? Study Links Drugs to Reduced Risk in Obesity-Related Cases

Mary Caffrey

Drugs first approved to treat diabetes, which later became a top sellers to aid weight loss, are associated with reduced risk of obesity-related cancer.

May 22nd 2025

AI Can Boost Accuracy When Classifying HER2-Low, HER2-Ultralow Breast Cancers, Findings Show

Mary Caffrey

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low breast cancers.